This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ironwood Pharmaceuticals Initiates Phase II Clinical Study Of IW-3718 In Refractory Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015.

“There are an estimated 7 million patients in the U.S. who suffer regularly from symptoms of GERD – such as heartburn and regurgitation – despite receiving the current standard of care of treatment with a proton pump inhibitor to suppress stomach acid production. For many of these refractory GERD patients, research suggests reflux of bile acid from the intestine into the stomach and esophagus may play an important role in their ongoing suffering,” said Michael Hall, MB. BCh., senior vice president, clinical development of Ironwood. “Refractory GERD is a significant unmet need among those suffering with gastrointestinal disorders, and we are investigating IW-3718 to assess whether it may help prevent bile acid reflux and provide relief for patients.”

Preliminary findings from non-clinical studies conducted by Ironwood and collaborators have shown that bile acids can cause relaxation (opening) of the lower esophageal sphincter, which allows reflux of contents from the stomach into the esophagus. Bile and bile acids were also shown to cause increased activity of esophageal nerve fibers in related non-clinical studies. Importantly, these study data suggest that a bile acid sequestrant may be able to block these actions. Collectively, these and other data provide additional evidence to suggest that bile acids could play a role in the pathophysiology of refractory GERD, and that a targeted bile acid sequestrant could have therapeutic utility in the treatment of this disorder.

IW-3718 is a novel gastric retention formulation of a bile acid sequestrant, created by Ironwood, and co-developed with Depomed Inc. through incorporation of its proprietary Acuform® drug delivery technology. IW-3718 is designed to deliver the bile acid sequestrant to the desired sites of action – specifically the stomach and duodenum (upper small intestine) – over an extended period of time. Data from non-clinical studies support the extended release profile of IW-3718.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs